Stifel analyst Paul Matteis reiterated a Buy rating on Karuna Therapeutics Inc. (NASDAQ: KRTX). The analyst comments: "We are reiterating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE